Jan 25, 2025, 12:41
Elvina Almuradova: Targeting c-MET overexpression is reshaping EGFR-mutant NSCLC treatment
Elvina Almuradova, Oncology Unit Lead at Can Hospitals Turkey, shared a post on X:
“Breaking News from Annals of Oncology! Targeting c-MET overexpression is reshaping EGFR-mutant NSCLC treatment!
- Teliso-V + Osimertinib combo:
- 50% ORR and 7.4 months PFS
- ADCs are the future for osimertinib-resistant NSCLC!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 25, 2025, 12:41
Jan 25, 2025, 12:41
Jan 25, 2025, 12:41
Jan 25, 2025, 12:41
Jan 25, 2025, 12:41
Jan 25, 2025, 12:41
Jan 25, 2025, 12:41
Jan 25, 2025, 12:41
Jan 25, 2025, 12:41
Jan 25, 2025, 12:41